1) plasminogen activitor inhibitor 1
纤维蛋白溶酶原激活物抑制剂
2) Plasminogen activator inhibitor (PAI)
纤维蛋白溶酶原激活因子抑制物
3) plasminogen activator inhibitor
纤溶酶原激活物抑制剂
1.
Objective To study the effect of Shuxuetong injection on brain microvascular endothelial cell secreting tissue-type plasminogen activator(t-PA) and plasminogen activator inhibitor-1(PAI-1).
目的研究疏血通注射液对脑微血管内皮细胞(BMECs)分泌组织型纤溶酶原激活物(t-PA)和纤溶酶原激活物抑制剂-1(PAI-1)的影响。
2.
The therapeutic effect and changes of neurofunction deficit score, tissue type plasminogen activator (tPA), plasminogen activator inhibitor (PAI), antithrombin Ⅲ (AT Ⅲ), th.
观察两组患者治疗后有效率 ,治疗前后神经功能缺损评分、组织型纤溶酶原激活剂 (tPA)、纤溶酶原激活物抑制剂 (PAI)、抗凝血酶 Ⅲ (AT Ⅲ )、血栓素B2 (TXB2 )及 6 -酮 -前列腺素F1α(6 keto PGF1α)的变化。
3.
The plasma tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI) activities were determined by chrimogenic substrate method.
方法:采用Olimpus-AU5400全自动生化分析仪测定53例SCI患者和55例健康者(对照组)血清Lp(α)水平,用发色底物法检测血浆组织型纤溶酶原激活物(t-PA)和纤溶酶原激活物抑制剂(PAI)活性,并对SCI患者的血清Lp(α)水平与血浆t-PA和PAI活性进行相关分析。
4) plasminogen activator inhibitor-1
纤溶酶原激活物抑制剂
1.
AIM:To observe the effects of angiotensin Ⅱ(AngⅡ) on PAI-1 (plasminogen activator inhibitor-1) and tPA (tissue type plasmingen activator) releases in isolated aorta and changes of fibrinolytic function in different states of RAS (renin-angiotensin system) in rats.
目的 :观察血管紧张素 (Ang )对大鼠主动脉纤溶酶原激活物抑制剂 (PAI- 1)、组织型纤溶酶原激活物(t PA)活性的影响及不同肾素活性状态下纤溶功能的变化。
5) Plasminogen activator inhibitor
纤溶酶原激活剂抑制物
1.
[Objective] The aim of this study was to observe the changes of tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor (PAI-1), tissue factor (TF), tissue factor pathway inhibitor (TFPI), thrombomodulin (TM) and von Willebrand Factor (vWF) of rats after different intensity training.
方法40只Waster大鼠进行不同强度量的游泳后,测定其血浆组织因子(TF)抗原、组织因子途径抑制物(TFPI)抗原、组织型纤溶酶原激活物(t-PA)活性、纤溶酶原激活剂抑制物-1(PAI-1)活性、抗血管性假性血友病因子(vWF)浓度和凝血酶调节蛋白(TM)抗原。
6) PAI-1
纤溶酶原激活物抑制剂
1.
Objective To investigate the effect of Fangjifulingtang on preventing proliferation of glomerular mesangial cells and the expression of PAI-1, so as to provide experimental evidence for Fangjifulingtang to cure chronic kidney disease.
目的观察防己茯苓汤加减方是否具有干预肿瘤坏死因子(TNF-α)诱导后肾小球系膜细胞增殖的作用及对纤溶酶原激活物抑制剂(PAI-1)的影响。
2.
Methods In 256 patients undergoing coronary angiography,tissue plasminogen activator(t-PA) & plasminogen activator inhibitor-1(PAI-1) were measured with usual procedures.
方法 根据受累冠脉数、狭窄程度及病变稳定性将 2 56例患者分别进行分组 ,测定并比较各组患者的组织型纤溶酶原激活物 (tissueplasminogenactivator,t-PA)及纤溶酶原激活物抑制剂 (plasminogenactivatorinhibitor- 1 ,PAI- 1 )血浆浓度。
3.
Objective To investigate the effect of aqueous plasminogen activator inhibitor-1 (PAI-1) on the formation of the anterior fibrinous membrane of PcIOL.
方法测定 31例白内障患者术前房水中纤溶酶原激活物抑制剂 (plasminogenactivatorinhibitor- 1,PAI- 1)含量 ,观察术眼术后PcIOL前纤维蛋白膜形成情况 ,根据术前患眼的病史 ,分为葡萄膜炎组、青光眼组及对照组并进行统计学分析。
补充资料：血纤维蛋白溶酶原激活剂
血纤维蛋白溶酶原激活剂plasminogen activator
血纤维蛋白溶酶原激活剂plasminogen activator 这是来自指血纤维蛋白溶酶原激活剂原的活性型．但也用作为具有使不活性的血纤维蛋白溶酶原变成有活性的血纤维蛋白溶酶的物质之总称．后者．在生理上可分为组织的（心脏、肺、前列腺、副肾、子宫等组织的激活剂）、血液的（白血球、血小板等激活剂）和体液的物质（尿的尿激酶、来自乳汁、唾液等激活剂）．在牛等动物中，作为血纤维蛋白溶酶原激活剂的前体物质是激活剂原（proactivator），这些激活剂原通过链激酶和溶解激酶（lysokinase）的作用，活化成为血纤维蛋白溶酶原激活剂。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条